Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/30648
Title: | Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management | Authors: | Cuker, Adam Bass, Ann D. Nadj, Congor Agius, Mark A. Steingo, Brian Selmaj, Krzysztof W. Thoits, Timothy Guerreiro, Alexandre VAN WIJMEERSCH, Bart Ziemssen, Tjalf Meuth, Sven G. LaGanke, Christopher C. Thangavelu, Karthinathan Rodriguez, Claudio E. Baker, Darren P. Margolin, David H. Jannsens, Ann |
Issue Date: | 2020 | Publisher: | SAGE PUBLICATIONS LTD | Source: | MULTIPLE SCLEROSIS JOURNAL, 26 (1) , p. 48 -56 | Abstract: | Background: Alemtuzumab is a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS), and immune thrombocytopenia (ITP) has been identified as a risk. Objective: To examine ITP incidence, treatment, and outcomes during the clinical development of alemtuzumab for RRMS and discuss postmarketing experience outside clinical trials. Methods: CAMMS223 and Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis (CARE-MS) I and II investigated two annual courses of alemtuzumab 12 mg (or 24 mg in CAMMS223/CARE-MS II) versus subcutaneous interferon beta-1a three times per week. Patients completing core studies could enroll in an extension. Monthly monitoring for ITP continued until 48 months after the last alemtuzumab infusion. Results: Of 1485 alemtuzumab-treated MS patients in the clinical development program, 33 (2.2%) developed ITP (alemtuzumab 12 mg, 24 [2.0%]; alemtuzumab 24 mg, 9 [3.3%]) over median 6.1 years of follow-up after the first infusion; most had a sustained response to first-line ITP therapy with corticosteroids, platelets, and/or intravenous immunoglobulin. All cases occurred within 48 months of the last alemtuzumab infusion. Postmarketing surveillance data suggest that the ITP incidence is not higher in clinical practice than in clinical trials. Conclusion: Alemtuzumab-associated ITP occurs in approximately 2% of patients and is responsive to therapy. Careful monitoring is key for detection and favorable outcomes. | Notes: | Cuker, A (reprint author), Hosp Univ Penn, Dept Med, 3 Dulles,3400 Spruce St, Philadelphia, PA 19104 USA.; Cuker, A (reprint author), Hosp Univ Penn, Dept Pathol & Lab Med, 3 Dulles,3400 Spruce St, Philadelphia, PA 19104 USA. adam.cuker@uphs.upenn.edu |
Other: | Cuker, A (reprint author), Hosp Univ Penn, Dept Med, 3 Dulles,3400 Spruce St, Philadelphia, PA 19104 USA, Hosp Univ Penn, Dept Pathol & Lab Med, 3 Dulles,3400 Spruce St, Philadelphia, PA 19104 USA. adam.cuker@uphs.upenn.edu | Keywords: | Alemtuzumab;disease-modifying therapy;immune thrombocytopenia;relapsing-remitting multiple sclerosis;safety | Document URI: | http://hdl.handle.net/1942/30648 | ISSN: | 1352-4585 | e-ISSN: | 1477-0970 | DOI: | 10.1177/1352458518816612 | ISI #: | WOS:000506058600008 | Rights: | The Author(s), 2019. Article reuse guidelines: sagepub.com/journalspermissions | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2021 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
adam.pdf | Published version | 299.38 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
8
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
24
checked on May 2, 2024
Page view(s)
38
checked on Sep 7, 2022
Download(s)
8
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.